Resiniferatoxin clinical trials
How each study uses resiniferatoxin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the resiniferatoxin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 4
Sorrento Therapeutics, Inc. (7) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · National Institutes of Health Clinical Center (CC) (1) · Grünenthal GmbH (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Medical University of Vienna (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test resiniferatoxin.
- Dec 2026Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone PainPhase 1/2 · National Institute of Neurological Disorders and Stroke (NINDS)
Studies
Open first, then newest update. How each study uses resiniferatoxin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone PainNot yet recruitingPhase 1/2National Institute of Neurological Disorders and Stroke (NINDS)NCT02522611Written as ResiniferatoxinHow we know
- Resiniferatoxin to Treat Severe Pain Associated With Advanced CancerCompletedPhase 1National Institute of Dental and Craniofacial Research (NIDCR)NCT00804154Written as Intrathecal ResiniferatoxinHow we know
- Resiniferatoxin for the Management of Refractory Morton s Neuroma PainCompletedPhase 1National Institutes of Health Clinical Center (CC)NCT05695339Written as ResiniferatoxinHow we know
- Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced CancerSuspendedPhase 2Sorrento Therapeutics, Inc.NCT05067257Written as ResiniferatoxinHow we know
- Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee OsteoarthritisStatus unknownPhase 2Sorrento Therapeutics, Inc.NCT04885972Written as ResiniferatoxinHow we know
- Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and RemissionTerminatedPhase 4Medical University of ViennaNCT05116228Written as 500mg RTX GroupHow we know
- Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer PainWithdrawnPhase 3Sorrento Therapeutics, Inc.NCT04572776Written as ResiniferatoxinHow we know
- Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is DelayedWithdrawnPhase 3Sorrento Therapeutics, Inc.NCT04386980Written as ResiniferatoxinHow we know
- A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the KneeWithdrawnPhase 3Sorrento Therapeutics, Inc.NCT04044742Written as ResiniferatoxinHow we know
- Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint PainCompletedPhase 1Grünenthal GmbHNCT02566564Written as LopainHow we know
- Study of Resiniferatoxin for Knee Pain in Moderate to Severe OsteoarthritisCompletedPhase 1Sorrento Therapeutics, Inc.NCT03542838Written as ResiniferatoxinHow we know
- Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer PainCompletedPhase 1Sorrento Therapeutics, Inc.NCT03226574Written as ResiniferatoxinHow we know
Codes
What other systems call resiniferatoxin · ClinicalTrials.gg INT002788
- MeSH (NLM) C024353resiniferatoxinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) A5O6P1UL4IRESINIFERATOXINConfirmed FDA, NLM, Wikidata
- Wikidata Q3277888resiniferatoxinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1214ResiniferatoxinOne source FDA
- DrugBank DB06515One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C024353 | resiniferatoxin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | A5O6P1UL4I | RESINIFERATOXIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3277888 | resiniferatoxin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1214 | Resiniferatoxin | One source FDA |
| DrugBank | DB06515 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.